Zymeworks completes acquisition of Theravance Biopharma

Zymeworks completed its previously announced acquisition of Theravance Biopharma, adding the company to its portfolio of healthcare assets.

The deal supports a strategy to build diversified revenue streams, combining internal R&D with commercial product and royalty cash flows.

A management conference call is scheduled for Sept. 28 at 8:30 a.m. ET to review final transaction details.